Lewy bodies, widely present in Parkinson's disease, are often seen in Alzheimer-type pathologies. While Alzheimer's disease is characterized by an accumulation of amyloid-beta, Parkinson's is by an accumulation of alpha-synuclein. Some studies have also shown that the accumulation of these two aggregates can be correlated. Here, the correlation between amyloid-beta peptides and phosphorylation of alpha-synuclein is studied in postmortem human brain samples, from different cases of Parkinson's disease and dementia with Lewy bodies, and in a human neuroblastoma cell line overexpressing human alpha-synuclein. The results showed that insoluble and soluble phosphorylated alpha-synuclein correlated positively and negatively, respectively, with insoluble amyloid-beta. Moreover, amyloid-beta and insoluble phosphorylated alpha-synuclein levels were higher in demented than in non-demented patients. Insoluble alpha-synuclein also correlated positively with the Braak stage but negatively with the mini-mental state examination. Furthermore, neuroblastoma cells exposed to aggregated amyloid-beta 42 had increased levels of phosphorylated alpha-synuclein. In summary, this study shows that phosphorylated alpha-synuclein concentration in brain tissue correlates with amyloid-beta levels and with the dementia state, which could be potentially used to monitor the Lewy body disease-induced dementia.
Evaluating the relationship between amyloid-β and α-synuclein phosphorylated at Ser129 in dementia with Lewy bodies and Parkinson’s disease
The IE from MS no longer understands current scripting languages, the latest main version (version 11) is from 2013 and has not been further developed since 2015.
Our recommendation: Use only the latest versions of modern browsers, for example Google Chrome, Mozilla Firefox or Microsofrt Edge, because only this guarantees you sufficient protection against infections and the correct display of websites!